



## Berkshire West Area Prescribing Committee Policy Statement

<b>Drug Name</b>	Ingenol mebutate (Picato®)
<b>Indication under review</b>	Topical treatment of actinic keratosis in adults
<b>Policy No:</b>	APC 007
<b>Date of Issue:</b>	November 2014
<b>Review Date:</b>	November 2017
<b>Policy Statement:</b> Ingenol mebutate (Picato®) is indicated for the treatment of actinic keratosis (AK) in adult patients.	
<b>Traffic Light Status</b>	<b>Green</b>
<b>Key Points considered:</b>	
<ul style="list-style-type: none"> <li>• In double-blind, randomised, vehicle-gel controlled trials of patients with actinic keratosis; ingenol mebutate gel was associated with significantly higher rates of complete lesion clearance compared with vehicle gel. In pooled analyses of these studies, the percentages of patients with complete clearance of lesions after treatment with ingenol mebutate gel were 42.2% (face/scalp studies) and 34.1% (trunk/extremities studies), compared with 3.7% and 4.7% respectively of patients receiving vehicle gel (<math>p &lt; 0.001</math> in both cases).</li> <li>• The evidence for the efficacy of ingenol mebutate gel was considered to be relatively strong. Four randomised placebo-controlled trials have demonstrated the superiority of ingenol mebutate gel compared with placebo for complete and partial clearance of AK lesions.</li> <li>• Treatment period is shorter than currently available therapies and the cost of treatment is similar to that of available treatments.</li> <li>• Local clinicians support the use of this treatment.</li> </ul>	
<b>References:</b>	
<ol style="list-style-type: none"> <li>1. NICE ESNM14: Actinic keratosis: ingenol mebutate gel Lebwohl M, Swanson N, Anderson LL et al. (2012) <a href="#">Ingenol mebutate gel for actinic keratosis</a>.</li> <li>2. Regional Drugs and Therapeutics Centre Evaluation report Newer Topical Therapies for Actinic Keratosis April 2013</li> <li>3. Midlands Therapeutics Review and Advisory Committee. Commissioning Support Ingenol mebutate (Picato®) for the treatment of actinic keratosis.</li> <li>4.</li> </ol>	
<b>Date taken to APC:</b>	5 <sup>th</sup> November 2014
<b>Date Ratified by MMC on Behalf of the Board:</b>	12 <sup>th</sup> November 2014